Semaglutide for Smoking Cessation in Patients With Diabetes

Sponsor
Ottawa Heart Institute Research Corporation
Study ID
NCT07059377
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
  • Nicotine replacement — DRUG
    Nicotine patch plus short-acting NRT gum or lozenge

Study Details

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Key Dates

Start date
Feb 13, 2026
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    Semaglutide + Combination NRT for up to 6 months
  • Active Comparator: Control
    Combination NRT for up to 6 months

Primary Outcome Measure

Project success [ Time Frame: 12 months ]

Central Contacts

Related Studies